https://www.barrons.com/articles/sarepta-stock-gene-therapy-duchenne-muscular-dystrophy-fda-cc01c057
0
0
6/22/23 at 7:43pm
Organization
Barron's
Author
Josh Nathan-Kazis
35 words
0
Comments
The decision marks the first approval of a gene therapy to treat DMD, a fatal and progressive disease that manifests in young children.
You are the first to view
Create an account
or login to join the discussion